CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Summary

This study is to determine the maximum tolerated dose(MTD), dose limiting toxicity(DLT), safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination with Bortezomib and Dexamethasone in patients with Previously Treated Multiple Myeloma.

Timeline

Start

2017-01

Primary completion

2021-04

Completion

2022-11

Drugs

Indications